Brian Andrew Jonas, M.D., Ph.D.- HMA-Venetoclax for MDS/AML

Editor

1 year ago

Brian Andrew Jonas, M.D., Ph.D.- Hematology and Oncology – Hematology and Oncology – UC Davis Comprehensive Cancer Center

The presentation discusses the management and treatment strategies for patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) receiving hypomethylating agents (HMA) in combination with venetoclax.

AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/

AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/

MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/

aml-allus2023.md-education.com

Brian Andrew Jonas, M.D., Ph.D. discusses various aspects of this treatment approach, including dosing regimens, response assessments, infectious prophylaxis, management of cytopenias and toxicities, potential alternative schedules (such as shorter cycles or weekly dosing), considerations for specific mutations (IDH1, IDH2, TP53, etc.), and the role of triple combinations. The presentation emphasizes the need for dose modifications, supportive care measures, and careful patient management to achieve optimal outcomes.